RCS - Nexsen Biotech Pty - Director Appointment

Singular HealthAnnouncement

21/02/2024 08:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240221:nRSU8154Da&default-theme=true

RNS Number : 8154D  Nexsen Biotech Pty Ltd  21 February 2024

NEXSEN Biotech

("NEXSEN" or the "Company)

 

Strengthens the Board with the Appointment of Dr Martina Mariano as
Non-Executive Director

 

Brings industry expertise and biotech commercialisation experience to the
Board

 

Nexsen Biotech, the developer of innovative and accessible, rapid diagnostic
tests to transform outcomes of Group B Strep ("GBS"), announces the
appointment of Dr Martina Mariano as a Non-Executive Director.

 

 

 

Martina has over a decade of experience in the molecular biology industry
having held roles at a number of leading research institutes across Europe,
the US and Australia.

 

She is currently the Chief Commercial Officer at ASX-listed Singular Health
Group, a medical technology company utilising advanced technologies to develop
patient-specific solutions, where she has built the company's successful
Global partner program and is responsible for commercial strategy.

 

Martina has a Masters in Genetics and Molecular Biology from the Sapienza
University of Rome, a Masters in Forensic Genetics from the University of Rome
"Tor Vergata" and a PhD in Medicine from the University of Western
Australia.

 

Tom Hanly, Managing Director of Nexsen commented: "We are delighted that
Martina is joining our Board at this exiting time. Her detailed knowledge of
medical diagnostics combined with commercial experience and business
development expertise will be invaluable to Nexsen as we begin to execute the
commercial strategy of our lead product StrepSure® for Group B Streptococcus
(GBS).

 

"GBS is a highly prevalent and potentially fatal disease and there is a
significant unmet global need for an accessible, accurate diagnostic test to
transform outcomes of this disease. We believe StrepSure®, our rapid,
low-cost, easy-to-use, highly accurate point-of-care test, has the potential
to save lives and radically improve outcomes in neonatal care. We look
forwarded to working with Martina as we work towards bringing this important
product to market."

 

Dr Martina Mariano commented: "I am thrilled and honoured to embark on this
journey as a Director of Nexsen Biotech and collaborate closely with both the
Board and management team. Together, we will drive the advancement of
cutting-edge rapid diagnostic solutions for GBS infections during pregnancy. I
look forward to serving on the Board and contributing to the Company's
success."

 

--Ends--

 Enquiries:

 

 Nexsen Biotech                                  Via Walbrook

 Tom Hanly, Managing Director                    nexsen@walbrookpr.com (mailto:feedbackplc@walbrookpr.com)

 Mark Muzzin, Chairman

 Walbrook PR Ltd (PR and IR Advisers to Nexsen)  Tel: 020 7933 8780 or nexsen@walbrookpr.com (mailto:nexsen@walbrookpr.com)
 Nick Rome/Stephanie Cuthbert/

 Joe Walker/Louis Ashe-Jepson

 

About Nexsen Biotech

 

Nexsen is a specialist developer of rapid sensor technologies. The Company is
addressing a significant unmet global need for an accessible, accurate
diagnostic test to transform outcomes of Group B Strep; a highly prevalent and
potentially fatal disease, with its lead proprietary product StrepSure®, a
rapid, low-cost, easy-to-use, highly accurate point -of-care test.

 

Routine testing for GBS is available in many developed markets, with the
exception of the UK, however current tests are lab based, expensive, time
consuming or inaccurate. There are currently no point-of- care, rapid
diagnostic tests available or in development. As a result, accessible GBS
testing is unavailable for millions of women worldwide and it is a particular
issue in rural areas, high-risk communities & developing nations.

 

Routes to market for StrepSure will include adoption by national health
agencies, self-screening, NGO opportunities in developing countries and
philanthropic organisations.

 

Broader opportunities within GBS testing include Infants, UTIs, elderly,
Immuno-Compromised future epidemics in addition to the potential to
develop/license the technology for other sectors (veterinary, agriculture,
environment, and food sectors).

 

More information can be found here: NEXSEN BIOTECH | Saving Lives. Making a
Real (https://www.nexsen.bio/) Difference (https://www.nexsen.bio/)

 

About Group B Streptococcus (GBS)

 

Group B Streptococcus (GBS) is a highly prevalent and potentially fatal
disease. It is found in around 1 in 5 expecting mothers and can have fatal
implications on newborns. It is the single largest maternal health problem
faced by mothers and newborn children, however with accurate diagnosis it can
be easily and inexpensively be treated with antibiotics.

 

According to the first global study of GBS funded by a grant from the Gates
Foundation, 21.7 million pregnant women carry the GBS bacteria. Most are
unidentified and untreated. The World Health Organisation (WHO) estimates that
12.1%, 314,600, of the 2.6 million stillbirths per year may be caused by the
GBS infection.

 

If a carrier of Group B Strep is not treated with antibiotics during labour,
the baby's risk of becoming colonised with GBS is approximately 50%, with the
further risk of developing a serious, life-threatening infection in the order
of between 1% to 2%. When treated with antibiotics during labour, the risk of
the baby developing an early GBS infection drops by c.80%.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAPPUBCPUPCGAU